Advancing a New Generation of Ophthalmology Therapies
Built on a foundation of Wnt pathway biology, our pipeline features a growing portfolio of antibody therapeutics targeting ophthalmic diseases with significant unmet medical need.
Lead Programs
Glossary: FZD – frizzled; VEGF – Vascular Endothelial Growth Factor; IL-6 – interlukin-6; AMD – Age-Related Macular Degeneration; DME – Diabetic Macular Edema; UME – Uveitic Macular Edema;
*Strategic Collaboration with Boehringer Ingelheim
SZN-413 | Target: FZD4
SZN-413 is a targeted bispecific Wnt agonist antibody for the treatment of retinal vascular diseases such as wet AMD and DME. Licensed to Boehringer Ingelheim, it has shown preclinical potential to fully reverse retinopathy by simultaneously restoring blood flow to oxygen-starved areas of the retina and fixing leaky blood vessels.
SZN-8141 | Target: FZD4, VEGF
SZN-8141 is a bifunctional antibody that combines FZD4-targeted Wnt agonism with VEGF inhibition in a single molecule. SZN-8141 is designed to improve visual function and provide durable anatomic control in patients with wet AMD and DME.
SZN-8143 | Target: FZD4, VEGF, IL-6
SZN-8143 is a trifunctional antibody that addresses the key mediators of vascular leakage and inflammation in retinal conditions such as DME, AMD, and uveitic macular edema to inflammation. It combines Wnt agonism (FZD4 activation) with VEGF and IL-6 inhibition.
SZN-113 | Target: FZD1, FZD2, FZD7
SZN-113 is an antibody that agonizes multiple Wnt receptors (FZD1, FZD2, and FZD7). It has shown preclinical efficacy in models of Fuchs’ corneal endothelial dystrophy and photoreceptor degeneration.
With multiple investigational new drug applications planned, our pipeline is advancing toward a future in which therapies can preserve and restore the vision of millions of people worldwide.